- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022
Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced that the first patient was dosed in the OPTIC phase 1 trial evaluating ADVM-022 for patients with wet age-related macular degeneration (wet AMD). As quoted in the press release: “We are excited to announce the first …
Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced that the first patient was dosed in the OPTIC phase 1 trial evaluating ADVM-022 for patients with wet age-related macular degeneration (wet AMD).
As quoted in the press release:
“We are excited to announce the first patient dosed in our OPTIC phase 1 trial assessing a potential single intravitreal administration of ADVM-022 for wet AMD,” said Leone Patterson, chief executive officer of Adverum Biotechnologies. “This milestone is the next step in bringing a new meaningful option to patients, that may provide long-lasting therapy without the need of chronic or frequent anti-VEGF injections. We look forward to providing an interim update of this phase 1 by the first quarter of 2020.”
“While significant advances have been made in the management of wet AMD with the introduction of anti-VEGF therapies, there remains a need to address the treatment burden and suboptimal outcomes patients face from the need of repeated dosing,” said Dr. David S. Boyer, Partner at Retina-Vitreous Associates Medical Group and Clinical Professor of Ophthalmology at University of Southern California/Keck School of Medicine. “I am encouraged by the early data on ADVM-022, the potential to provide long-term durability with a single administration of an anti-VEGF therapy for patients and the ease of intravitreal delivery of ADVM-022, which utilizes the current standard of care delivery method. With these combined, ADVM-022 has the potential to be the next paradigm shift in treating wet AMD.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.